Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response

Cell surface expression of the human cytomegalovirus (HCMV) major envelope glycoprotein complex, gp55-116 (gB), was studied by using monoclonal antibodies and an HCMV gp55-116 (gB) recombinant vaccinia virus. HCMV-infected human fibroblasts and recombinant vaccinia virus-infected HeLa cells expresses three electrophoretically distinct proteins of Mr 170,000, 116,000, and 55,000 on their surface. These species have been previously identified within infected cells and purified virions. Two unique neutralizing epitopes were shown to be present on the cell surface gp55-116 (gB). Utilizing HeLa cells infected with the gp55-116 recombinant vaccinia virus as a specific immunosorbent, we have shown that approximately 40 to 70% of the total serum virus-neutralizing activity of a group of individuals with past HCMV infections was directed against this single envelope glycoprotein. The implications of this finding for vaccine development are discussed.

[1]  U. Utz,et al.  Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus , 1989, Journal of virology.

[2]  L. de Leij,et al.  Characterization of membrane antigens on human cytomegalovirus-infected fibroblasts recognized by human antibodies , 1989, Journal of virology.

[3]  W. Britt,et al.  A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. , 1989, Journal of virological methods.

[4]  W. Britt,et al.  Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus , 1989, Journal of virology.

[5]  W. Britt,et al.  Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB) , 1988, Journal of virology.

[6]  B. Kari,et al.  Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. , 1988, Virology.

[7]  M. Stinski,et al.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus , 1988, Journal of virology.

[8]  K. Sullivan,et al.  Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. , 1987, Annals of internal medicine.

[9]  B. Kari,et al.  Characterization of monoclonal antibodies reactive to several biochemically distinct human cytomegalovirus glycoprotein complexes , 1986, Journal of virology.

[10]  W. Britt,et al.  Primary Cytomegalovirus Infection in Pregnancy: Incidence, Transmission to Fetus, and Clinical Outcome , 1987 .

[11]  F. Hudecz,et al.  Immune responses to isolated human cytomegalovirus envelope proteins , 1986, Journal of virology.

[12]  W. Britt,et al.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus , 1986, Journal of virology.

[13]  T. Merigan,et al.  Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo. , 1985, Virology.

[14]  H. Masur,et al.  Herpesvirus infections in the acquired immune deficiency syndrome. , 1984, JAMA.

[15]  W. Britt.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. , 1984, Virology.

[16]  B. Chesebro,et al.  Identification of a unique erythroleukemia-associated retroviral gp70 expressed during early stages of normal erythroid differentiation , 1984, The Journal of experimental medicine.

[17]  T. Merigan,et al.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Flournoy,et al.  Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. , 1982, Reviews of infectious diseases.

[19]  C. Alford,et al.  Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. , 1982, The New England journal of medicine.

[20]  N. Famulari,et al.  Env gene products of AKR dual-tropic viruses: examination of peptide maps and cell surface expression , 1981, Journal of virology.

[21]  R. Betts,et al.  Cytolytic IgM antibody to cytomegalovirus in primary cytomegalovirus infection in humans. , 1981, The Journal of infectious diseases.

[22]  N. Flournoy,et al.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[23]  R. Whitley,et al.  EFFECT OF PRIMARY AND RECURRENT CYTOMEGALOVIRUS INFECTIONS UPON GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION , 1979, Transplantation.

[24]  S. Soong,et al.  Productive infection with cytomegalovirus and herpes simplex virus in renal transplant recipients: role of source of kidney. , 1978, The Journal of infectious diseases.

[25]  M. Hirsch,et al.  INFECTIOUS DISEASE SYNDROMES ATTRIBUTABLE TO CYTOMEGALOVIRUS AND THEIR SIGNIFICANCE AMONG RENAL TRANSPLANT RECIPIENTS , 1977, Transplantation.

[26]  M. Stinski.  Human cytomegalovirus: glycoproteins associated with virions and dense bodies , 1976, Journal of virology.

[27]  A. Gershon,et al.  Zoster immune globulin. A further assessment. , 1970, The New England journal of medicine.

[28]  P. Brunell,et al.  Prevention of varicella by zoster immune globulin. , 1969, The New England journal of medicine.

[29]  G. Enders.  [Perinatal infections]. , 1988, La Ricerca in clinica e in laboratorio.

[30]  R. Gale,et al.  Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. , 1987, Annals of internal medicine.

[31]  Jaap M Middeldorp,et al.  Killing of human cytomegalovirus-infected fibroblasts by antiviral antibody and complement. , 1986, The Journal of infectious diseases.